ReviewScience China. Life sciences2026
Emerging biotechnological approaches in alcoholic liver disease: natural compounds, delivery systems, and translational potential.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcoholic liver disease (ALD), resulting from chronic and excessive alcohol consumption, remains a major global public health burden. However, its underlying mechanisms are incompletely elucidated, and there are no specific biomarkers or effective pharmacological therapies currently available. Clinically, ALD diagnosis largely relies on patients' self-reported drinking history and nonspecific biochemical or imaging findings, which limits accurate detection and targeted treatment. Consequently, there is an urgent need for safe, accessible, and effective preventive strategies to alleviate ALD progression. Recent studies have demonstrated that dietary regulation and food-derived bioactive compounds-such as polyphenols, probiotics, and fatty acids-can effectively attenuate alcohol-induced oxidative stress, inflammation, and gut-liver axis dysfunction. This review systematically summarizes recent advances (2020-2025) in the study of dietary bioactive compounds with protective roles against ALD, focusing on their molecular mechanisms, including antioxidative, anti-inflammatory, and microbiota-modulating effects. Furthermore, the paper highlights biotechnological innovations in enhancing the efficacy of bioactive compounds, such as advanced delivery systems, processing technologies, and functional food design, which improve the stability, bioavailability, and targeted efficacy of these compounds. Accumulating evidence supports the translational potential of nutrition-based interventions in preventing and managing ALD. However, significant challenges remain, including inter-individual variability, safety validation, and regulatory acceptance. Looking forward, precision nutrition, next-generation probiotics (NGPs), intelligent delivery systems, AI-driven formulation design, and sustainable food sources are expected to drive innovation in ALD prevention. Overall, this review aims to provide a timely and comprehensive overview of emerging nutrition-based strategies, offering valuable insights for developing scientific, practical, and health-promoting nutritional interventions against ALD.
Indexed as
Identifiers
42886439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.